BioNTech SE
NASDAQ: BNTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin
- Employees
- 6,772
- Headquarters
- Mainz, Germany
- IPO year
- 2019
- Market cap
- $23.0B
- Website
- https://www.biontech.de
Loading BNTX…
Loading profile data…Frequently asked questions about BNTX
What does BioNTech SE (BNTX) do?
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for a...
Where does BNTX trade?
BioNTech SE (BNTX) trades on the NASDAQ Global Select.
What sector is BNTX in?
BioNTech SE (BNTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioNTech SE?
Ugur Sahin is the chief executive officer of BioNTech SE (BNTX).
Where is BioNTech SE headquartered?
BioNTech SE is headquartered in Germany.
Does BNTX pay a dividend?
BioNTech SE (BNTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BNTX go public?
BioNTech SE (BNTX) completed its initial public offering in 2019.
Is BNTX an ADR?
Yes — BNTX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. BioNTech SE reporting and dividends follow the underlying issuer.